U.S., Feb. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07425899) titled 'A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult Participants' on Feb. 17.
Brief Summary: This is a Phase 1 study to investigate safety and pharmacokinetics of ABBV-722 and Upadacitinib following multiple oral doses in healthy adult participants.
Study Start Date: Feb. 23
Study Type: INTERVENTIONAL
Condition:
Healthy Volunteer
Intervention:
DRUG: ABBV-722
Oral
DRUG: Upadacitinib
Oral
Recruitment Status: NOT_YET_RECRUITING
Sponsor: AbbVie
Published by HT Digital Content Services with permission from Health Daily Digest....